SCHEMBL25544957

SCHEMBL25544957

Cc1cc(-c2c(C3CCOCC3)c(Cl)nc3cc(O)ccc23)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.38
PIK3CA P42336 1/20 0.38
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPK10 P53779 3/20 0.36
TLR8 Q9NR97 8/20 0.35
TLR9 Q9NR96 7/20 0.35
TLR7 Q9NYK1 7/20 0.35
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
PDE2A O00408 1/20 0.33
IRAK1 P51617 2/20 0.33
IRAK4 Q9NWZ3 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25544956 0.90 TLR9 (0.35) PIK3CDTLR8TLR9TLR7PDE2A
SCHEMBL23887857 0.86 DYRK1A (0.40) PIK3CDPIK3CAALDH1A1HPGDTSHR
SCHEMBL23887870 0.82 PARP14 (0.44) TLR8CNR2
SCHEMBL25544951 0.81 PDE2A (0.36) PIK3CDPIK3CATLR8TLR9TLR7
SCHEMBL23887699 0.79 ALDH1A1 (0.39) PIK3CDPIK3CAALDH1A1GAAHPGD
SCHEMBL23895721 0.79 TOP1 (0.37) PIK3CDPIK3CAALDH1A1GAAHPGD
SCHEMBL23887762 0.78 DYRK1A (0.40) PIK3CDPIK3CAALDH1A1GAAHPGD
SCHEMBL23895975 0.76 PIK3CA (0.40) PIK3CDPIK3CAALDH1A1GAAHPGD
SCHEMBL23895733 0.75 IRAK4 (0.37) ALDH1A1GAAHPGDALOX15TSHR
SCHEMBL25557363 0.73 PIK3CD (0.38) PIK3CDPIK3CAMAPK10TLR8TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 PIK3CD 3479/4885PIK3CA 4114/4885ALDH1A1 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.